Interviews

Eticho has organized a European Expert Forum on Triple Negative Breast Cancer on Thursday 7 October 2010 in Milan, Italy. The goal of this forum was to discuss the emergence of TNBC as a separate subtype in breast cancer, its different clinical, patho-morphological and genomic variations. This forum was also designed to obtain a consensus on which clinical subtypes can be classified as TNBC, what the associated treatment approach should be today and what we can expect in the near future. Eticho invites you to view expert interviews from several participants covering questions and topics discussed during this very successful and interesting meeting.

	Wolfgang Eiermann, MD PhD Rotkreuzklinikum München, Munich, Germany The Need for Consensus on TNBC	Barbro Linderholm, MD PhD Karolinska Institute and University Hospital, Stockholm, Sweden Negativity: can it be Acquired?
	Frédérique Penault-Llorca, MD PhD Centre Jean Perrin, Clermont-Ferrand, France Keeping it Simple: Defining TNBC	Evangelia Razis, MD PhD Hygeia Hospital, Maroussi, Greece The TNBC Subgroup: a Dynamic Population
	Bernhard Pestalozzi, MD University Hospital Zürich, Zürich, Switzerland Relevance of Basal-like vs. Non Basal-like in Clinical Reality	PierFranco Conte, MD PhD University of Modena and Reggio Emilia, Modena, Italy The Importance of BRCA Status in TNBC and Clinical Reality
	Guiseppe Viale, MD PhD European Institute of Oncology, Milan, Italy Consensus Reached on Markers in TNBC	Christos Sotiriou, MD PhD Julet Bordet Institute, Brussels, Belgium Defining Targets in the Light of the Reached Consensus
	Barry Gusterson, MD PhD University of Glasgow, Glasgow, UK Difficulties in Defining TNBC	Joseph Gligorov, MD Tenon University Hospital, Paris, France Clinical Challenges and what to Expect in the Near Future

	Moderator Isolde van Alderwegen